Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodolfo Hurle

Showing results (161-170 of 183) with videos related to

Pageof 19
Sort By:
European Urology Focus|May 20, 2025
Long-term Oncological Outcomes for Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin (BCG): A Comparative Analysis of Adequate Versus Inadequate BCG TreatmentPietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
Urologic Oncology|February 1, 2024
Time to progression is the main predictor of survival in patients with high-risk nonmuscle invasive bladder cancer: Results from a machine learning-based analysis of a large multi-institutional databaseAnnamaria Porreca, Marta Di Nicola, Giuseppe Lucarelli, et al.
BJU International|February 19, 2025
Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancerPietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
Minerva Urology and Nephrology|January 13, 2021
Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicenter studyMatteo Ferro, Michele Marchioni, Giuseppe Lucarelli, et al.
European Urology Focus|August 22, 2021
Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre CollaborationChiara Lonati, Philipp Baumeister, Luca Afferi, et al.
Clinical Genitourinary Cancer|September 4, 2023
Advanced Age Impacts Survival After Radical Nephroureterectomy for Upper Tract Urothelial CarcinomaMatteo Ferro, Sever Chiujdea, Mihai Dorin Vartolomei, et al.
Urologic Oncology|April 12, 2026
The impact of age in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-GuérinPietro Scilipoti, Paolo Zaurito, Mattia Longoni, et al.
World Journal of Urology|February 26, 2022
Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaborationChiara Lonati, Luca Afferi, Andrea Mari, et al.
Urologic Oncology|April 4, 2026
Risk stratification of Ta high-grade non-muscle-invasive bladder cancer: Insights from a multicenter cohort studyPaolo Zaurito, Pietro Scilipoti, Mattia Longoni, et al.
Frontiers in Oncology|May 28, 2021
Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional AnalysisMatteo Ferro, Ottavio de Cobelli, Gennaro Musi, et al.
Pageof 19

Showing results (161-170 of 183) with videos related to

Sort By:
Pageof 19
European Urology Focus|May 20, 2025
Long-term Oncological Outcomes for Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin (BCG): A Comparative Analysis of Adequate Versus Inadequate BCG TreatmentPietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
Urologic Oncology|February 1, 2024
Time to progression is the main predictor of survival in patients with high-risk nonmuscle invasive bladder cancer: Results from a machine learning-based analysis of a large multi-institutional databaseAnnamaria Porreca, Marta Di Nicola, Giuseppe Lucarelli, et al.
BJU International|February 19, 2025
Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancerPietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
Minerva Urology and Nephrology|January 13, 2021
Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicenter studyMatteo Ferro, Michele Marchioni, Giuseppe Lucarelli, et al.
European Urology Focus|August 22, 2021
Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre CollaborationChiara Lonati, Philipp Baumeister, Luca Afferi, et al.
Clinical Genitourinary Cancer|September 4, 2023
Advanced Age Impacts Survival After Radical Nephroureterectomy for Upper Tract Urothelial CarcinomaMatteo Ferro, Sever Chiujdea, Mihai Dorin Vartolomei, et al.
Urologic Oncology|April 12, 2026
The impact of age in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-GuérinPietro Scilipoti, Paolo Zaurito, Mattia Longoni, et al.
World Journal of Urology|February 26, 2022
Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaborationChiara Lonati, Luca Afferi, Andrea Mari, et al.
Urologic Oncology|April 4, 2026
Risk stratification of Ta high-grade non-muscle-invasive bladder cancer: Insights from a multicenter cohort studyPaolo Zaurito, Pietro Scilipoti, Mattia Longoni, et al.
Frontiers in Oncology|May 28, 2021
Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional AnalysisMatteo Ferro, Ottavio de Cobelli, Gennaro Musi, et al.
Pageof 19